cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major Presenters to provide first look

Due to significant likelihood of under-reporting, minor birth defects were not included in the evaluation

[DOI] [PubMed] [Google Scholar] 89.El Hajj EC, El Hajj MC, Sykes B, et al

Ania Jastreboff, a leading obesity researcher quoted in the piece, emphasized a critical principle for the high-dose era: We have to use the dose that the patient needs The underlying question is needing to approach and treat obesity as we would any other chronic disease. The challenge for providers is that there is no universal Goldilocks amount of weight loss

For more information: Lin-Shien Fu, MD, can be reached at [email protected].

Hold shift to jump forward or backward